stoxline Quote Chart Rank Option Currency Glossary
DBV Technologies S.A. (DBVT)
0.9786  -0.021 (-2.14%)    06-18 16:00
Open: 1.0085
High: 1.02
Volume: 10,898
Pre. Close: 1
Low: 0.9786
Market Cap: 94(M)
Technical analysis
2024-06-18 4:45:15 PM
Short term     
Mid term     
Targets 6-month :  1.37 1-year :  1.56
Resists First :  1.17 Second :  1.34
Pivot price 1.07
Supports First :  0.89 Second :  0.74
MAs MA(5) :  1.01 MA(20) :  1.11
MA(100) :  1.44 MA(250) :  2.08
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  23.8 D(3) :  28.2
RSI RSI(14): 33.1
52-week High :  4.42 Low :  0.83
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ DBVT ] has closed above bottom band by 14.8%. Bollinger Bands are 23.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.02 - 1.03 1.03 - 1.03
Low: 0.96 - 0.97 0.97 - 0.98
Close: 0.97 - 0.98 0.98 - 0.99
Company Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Headline News

Sat, 15 Jun 2024
DBV Technologies (NASDAQ:DBVT) Research Coverage Started at - Defense World

Sat, 15 Jun 2024
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at - MarketBeat

Thu, 13 Jun 2024
Short Interest in DBV Technologies S.A. (NASDAQ:DBVT) Decreases By 36.2% - MarketBeat

Wed, 05 Jun 2024
DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Yahoo Finance

Fri, 31 May 2024
DBV Technologies Announces ADS Ratio Change and Issues Notice - - TipRanks

Wed, 29 May 2024
DBV Technologies CMO sells shares worth over $1,400 By -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 96 (M)
Held by Insiders 4.334e+007 (%)
Held by Institutions 0 (%)
Shares Short 262 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.39e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 29.7 %
Return on Equity (ttm) -27.7 %
Qtrly Rev. Growth 1.494e+007 %
Gross Profit (p.s.) -47.87
Sales Per Share -72.92
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -94 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0.63
Stock Dividends
Dividend 0
Forward Dividend 260890
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android